Paratek Pharmaceuticals Analysis

PRTKDelisted Stock  USD 2.23  0.00  0.00%   
Paratek Pharmaceuticals is overvalued with Real Value of 1.88 and Hype Value of 2.23. The main objective of Paratek Pharmaceuticals delisted stock analysis is to determine its intrinsic value, which is an estimate of what Paratek Pharmaceuticals is worth, separate from its market price. There are two main types of Paratek Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Paratek Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Paratek Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Paratek Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Paratek Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Paratek Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Paratek Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

Paratek Stock Analysis Notes

About 55.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.11. Paratek Pharmaceuticals last dividend was issued on the 31st of October 2014. The entity had 1:12 split on the 31st of October 2014. Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts. Paratek Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people. To find out more about Paratek Pharmaceuticals contact FACC FAHA at 617 807 6600 or learn more at https://paratekpharma.com.

Paratek Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Paratek Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Paratek Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Paratek Pharmaceuticals is not yet fully synchronised with the market data
Paratek Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 150.79 M. Net Loss for the year was (63.57 M) with profit before overhead, payroll, taxes, and interest of 99.39 M.
Paratek Pharmaceuticals currently holds about 57.01 M in cash with (66.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03.
Roughly 55.0% of the company shares are owned by institutional investors

Paratek Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Paratek Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Paratek Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
2nd of November 2023
Upcoming Quarterly Report
View
21st of March 2024
Next Financial Report
View
30th of September 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of June 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Paratek Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 127.83 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Paratek Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Paratek Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Paratek Profitablity

Paratek Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Paratek Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Paratek Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Paratek Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Paratek Pharmaceuticals' profitability requires more research than a typical breakdown of Paratek Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.35) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.25) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.25.

Paratek Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Paratek Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Paratek Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Paratek Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Paratek Pharmaceuticals Predictive Daily Indicators

Paratek Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Paratek Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

About Paratek Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Paratek Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Paratek shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Paratek Pharmaceuticals. By using and applying Paratek Stock analysis, traders can create a robust methodology for identifying Paratek entry and exit points for their positions.
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts. Paratek Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Paratek Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run My Watchlist Analysis Now

   

My Watchlist Analysis

Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
All  Next Launch Module
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Consideration for investing in Paratek Stock

If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data